Effect of oral colestimide on the elimination of high-dose methotrexate in patients with primary central nervous system lymphoma--case report

Neurol Med Chir (Tokyo). 2005 Dec;45(12):650-2. doi: 10.2176/nmc.45.650.

Abstract

Delayed methotrexate (MTX) elimination occurred in two patients with primary central nervous system lymphoma undergoing high-dose MTX treatment. Oral administration of the anion exchange resin colestimide, which binds MTX effectively in vitro, effectively accelerated MTX elimination. Colestimide probably interrupts the enterohepatic circulation, and is a potential oral antidote to MTX toxicity.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Adult
  • Antimetabolites, Antineoplastic / pharmacokinetics*
  • Central Nervous System Neoplasms / drug therapy*
  • Epichlorohydrin / administration & dosage
  • Epichlorohydrin / pharmacology*
  • Humans
  • Imidazoles / administration & dosage
  • Imidazoles / pharmacology*
  • Lymphoma / drug therapy*
  • Male
  • Methotrexate / administration & dosage
  • Methotrexate / pharmacokinetics*
  • Middle Aged
  • Resins, Synthetic / administration & dosage
  • Resins, Synthetic / pharmacology*

Substances

  • Antimetabolites, Antineoplastic
  • Imidazoles
  • Resins, Synthetic
  • colestimide
  • Epichlorohydrin
  • Methotrexate